Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …

The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which
involve diverse organs, have varying biology, onset time, and severity. Herein, we identify …

Immune-related adverse events, particularly severe toxicities such as myocarditis, are major
challenges to the utility of immune checkpoint inhibitors (ICIs) in anticancer therapy. The …

Immune-related adverse events (irAEs) are a range of complications associated with the use
of immune-checkpoint inhibitors (ICIs). Two major classes of ICIs widely used are Cytotoxic …

Importance The spectrum of individual immune-related adverse events (irAEs) from anti–
programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immune …

Tumor mutational burden (TMB), the total number of somatic coding mutations in a tumor, is
emerging as a promising biomarker for immunotherapy response in cancer patients. TMB …

Immune-checkpoint inhibitors (ICIs) have transformed patient care in oncology but are
associated with a unique spectrum of organ-specific inflammatory toxicities known as …

Immune-checkpoint inhibitors (ICIs) have dramatically changed the management of
advanced cancers. Designed to enhance the antitumour immune response, they can also …

Autoimmune toxicity occurs in up to 60% of patients treated with immune checkpoint inhibitor
(ICI) therapy for cancer and represents an increasing clinical challenge for expanding the …

Immune checkpoint inhibitors (ICIs) improve clinical outcomes in patients suffering from
different types of cancer. Liver toxicity is one of the immune-related adverse events …